Faslodex and Intervertebral disc space narrowing - a phase IV clinical study of FDA data

Summary:

Intervertebral disc space narrowing is reported as a side effect among people who take Faslodex (fulvestrant), especially for people who are female, 50-59 old, also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Intervertebral disc space narrowing when taking Faslodex. It is created by eHealthMe based on reports of 19,135 people who have side effects when taking Faslodex from the FDA, and is updated regularly.

What is Faslodex?

Faslodex has active ingredients of fulvestrant. It is often used in breast cancer metastatic. eHealthMe is studying from 19,255 Faslodex users. Check the latest studies of Faslodex.

What is Intervertebral disc space narrowing?

Intervertebral disc space narrowing (spinal disc space narrowing) is found to be associated with 452 drugs and 315 conditions by eHealthMe. Check the latest studies of Intervertebral disc space narrowing.

On Jul, 05, 2026

19,135 people reported to have side effects when taking Faslodex.
Among them, 64 people (0.33%) have Intervertebral disc space narrowing.

Could Faslodex cause Intervertebral disc space narrowing?

Among these 64 people:

What is the gender of people who have Intervertebral disc space narrowing when taking Faslodex? *

female: 82.26 %
male: 17.74 %

What is the age of people who have Intervertebral disc space narrowing when taking Faslodex? *

What are other drugs people take besides Faslodex? *

What are other side effects people have besides Intervertebral disc space narrowing? *

Osteonecrosis Of Jaw (death of bone of jaw): 63 people, 98.44%
Stress And Anxiety: 54 people, 84.38%
Pain: 53 people, 82.81%
Metastases To Bone (cancer spreads to bone): 53 people, 82.81%
Back Pain: 47 people, 73.44%
Pain In Jaw: 44 people, 68.75%
Spinal Osteoarthritis (joint cartilage loss in spine): 43 people, 67.19%
Intervertebral Disc Degeneration (spinal disc degeneration): 40 people, 62.50%
Fall: 38 people, 59.38%
Atelectasis (partial or complete collapse of the lung): 37 people, 57.81%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 20 people, 31.25%
Neoplasm Malignant (cancer tumour): 10 people, 15.62%
Diabetes: 10 people, 15.62%
Hypersensitivity: 9 people, 14.06%
Metastatic Neoplasm (spreadable cancer tumour): 9 people, 14.06%
High Blood Pressure: 6 people, 9.38%
Resorption Bone Increased: 6 people, 9.38%
Anaemia (lack of blood): 3 people, 4.69%
Pain: 2 people, 3.12%
Quit Smoking: 2 people, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Faslodex and have Intervertebral disc space narrowing?

- Check whether Intervertebral disc space narrowing is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Faslodex:

Faslodex (19,255 reports)

Browse all side effects of Faslodex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intervertebral disc space narrowing:

Intervertebral disc space narrowing (452 drugs)

Browse all the conditions that are associated with Intervertebral disc space narrowing:

Intervertebral disc space narrowing (315 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fulvestrant (the active ingredients of Faslodex) and Faslodex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.